Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

Post by shawshank666on Nov 03, 2023 9:18am
130 Views
Post# 35715437

From the AGM

From the AGMI got this from the transcript of the AGM on the company's website.

In many cases, this sales cycle stage may repeat a few times. Where multiple decisionmakers are involved, salespeople may need to pitch and follow up with several stakeholders. As part of this stage, we have found that an evaluation period of 3-5 days is needed for the customer to decide whether to move forward with a purchase. Every evaluation to date has resulted in a customer deciding that they want to purchase. 

Did you read that. Every evaluation has resulted in a customer deciding they want to purchase. So we can stop worrying. (unless they have had no evaluations)
I noticed they stopped making projections as they did in 2022.
This is from the Dec.14,2022 news release again.
The Company had set a target of 40-45 systems committed to customers by year end. The company has received 6 purchase orders year to date, including orders from Europe, UK, and United States, has 3 installations being arranged and 5 more purchase orders are expected by end of January.
If there were 6 purchase orders year to date(for 2022)where is the revenue from those 6? And where's the revenue from 5 more purchase orders expected by the end of January(2023)? So they learned from their mistakes of setting targets and expectations. I didn't see a sales target for 2024 but if every evaluation ends up with purchase and every demo(3-4 demos per month)ends up with a purchase there's going to be a lot of revenue in 2024!!! Let's see what happens. I will believe it after you
SHOW ME THE MONEY
<< Previous
Bullboard Posts
Next >>